Galmed Pharmaceuticals Ltd. (GLMD) Given Average Recommendation of “Buy” by Analysts
Shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) have earned a consensus rating of “Buy” from the six analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $18.30.
A number of research firms recently commented on GLMD. Roth Capital began coverage on shares of Galmed Pharmaceuticals in a research note on Wednesday. They issued a “buy” rating and a $32.00 target price for the company. Zacks Investment Research upgraded shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.50 target price for the company in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Galmed Pharmaceuticals in a research note on Friday, November 10th. Maxim Group reiterated a “buy” rating and issued a $14.00 target price on shares of Galmed Pharmaceuticals in a research note on Thursday, November 9th. Finally, Seaport Global Securities reiterated a “buy” rating and issued a $19.00 target price on shares of Galmed Pharmaceuticals in a research note on Friday, October 6th.
An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. KCG Holdings Inc. bought a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 20,473 shares of the biopharmaceutical company’s stock, valued at approximately $100,000. KCG Holdings Inc. owned approximately 0.17% of Galmed Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 8.25% of the company’s stock.
Galmed Pharmaceuticals (NASDAQ GLMD) traded down $0.22 during mid-day trading on Wednesday, reaching $7.38. 32,800 shares of the company were exchanged, compared to its average volume of 35,245. Galmed Pharmaceuticals has a one year low of $3.04 and a one year high of $9.59.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.